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ABSTRACT 
 
Spinal muscular atrophy (SMA) is the leading genetic cause of infant mortality. SMA 
results from deletions or mutations of survival motor neuron 1 (SMN1), an essential 
gene. SMN2, a nearly identical copy, can compensate for SMN1 loss if SMN2 exon 7 
skipping is prevented. Among the many cis-elements involved in the splicing regulation 
of SMN exon 7, intronic splicing silencer N1 (ISS-N1) has emerged as the most 
effective target for an antisense oligonucleotide (ASO)-mediated splicing correction of 
SMN2 exon 7. Blocking of ISS-N1 by an ASO has been shown to fully restore SMN2 
exon 7 inclusion in SMA patient cells as well as in vivo. Here we review how ISS-N1 
targeting ASOs that use different chemistries respond differently in the various SMA 
mouse models. We also compare other ASO-based strategies for therapeutic splicing 
correction in SMA. Given that substantial progress on ASO-based strategies to promote 
SMN2 exon 7 inclusion in SMA has been made, and that similar approaches in a 
growing number of genetic diseases are possible, this report has wide implications. 
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INTRODUCTION 
 
Spinal muscular atrophy (SMA) is a leading neurodegenerative disease of 
children and infants (1-7). SMA is characterized by the progressive loss of α-motor 
neurons in the spinal cord, which leads to paralysis of the trunk and limbs and 
respiratory insufficiency (2-7). SMA is caused by the homozygous functional loss of the 
survival motor neuron 1 (SMN1) gene due to deletion, subtle mutation, or gene 
conversion (2-5). SMN2, a nearly identical copy of SMN1, fails to compensate for SMN1 
loss due to a critical C to T transition at the 6th position (C6U in transcript) in exon 7 (8). 
C6U leads to exon 7 skipping during pre-mRNA splicing of SMN2 (9); as a 
consequence, a truncated, dysfunctional and rapidly degraded protein (SMNΔ7) is 
produced (10,11). The defects caused by SMN1 deficiency can be compensated by 
increased copies of SMN2, which produces low levels of full-length SMN (12). 
Considering all SMA patients retain at least one functional copy of SMN2, it is 
reasonable to assume that strategies aimed at correcting SMN2 exon 7 splicing hold the 
promise for a treatment. Indeed, the postnatal increase of SMN levels through SMN2 
exon 7 splicing correction—by both small compounds and antisense oligonucleotides 
(ASOs)—provides substantial therapeutic benefits in animal models of SMA (13-16). 
Several recent reviews summarized the general progress in the rapidly evolving field of 
oligonucleotide research (17-21). This review is inspired by several independent reports 
in which different ASO chemistries against a single intronic target have shown 
unprecedented therapeutic benefits in various mouse models of SMA. Here we focus on 
challenges and lessons drawn from the recent ASO-based therapeutic approaches in 
SMA, and their implications for nucleic-acid-based therapy of a growing number of 
genetic diseases.  
 
Developing ASO-based splicing correction therapeutics is not a straight-forward 
task.  Splicing modulation using an ASO-mediated approach requires sequestration of a 
splicing cis-element (18). Since the majority of the human genome is transcribed (22), 
there is a substantial risk that an ASO could anneal to analogous sequences through 
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mismatch base pairing and have off-target effects. Furthermore, transcribed RNAs form 
secondary structures within microseconds of emerging from polymerase II (23-25). 
Thus, low annealing efficiency of ASOs with targets located in the structured region of 
transcripts results in reduced antisense response (26). Most RNA-interacting proteins 
recognize small sequence motifs. Therefore, unwanted interactions of proteins with 
ASOs could also contribute to reduced antisense efficacy. Hence, designing an ASO 
that does not interact with protein factors and anneals to a desired cis-element located 
within a structurally accessible region of RNA remains the most challenging aspect of 
developing an ASO-based therapeutic strategy.  
 
The degree of antisense response is dependent upon the strength of the targeted 
splicing cis-element as well as the nature of the context created by the duplex formed 
between the ASO and its target. Splicing is a dynamic process that involves numerous 
RNA-protein and RNA-RNA interactions (27-30), so it is safe to assume that permanent 
annealing of an ASO to its target affects several interactions and enforces remodeling of 
the RNA structure of the target and associated sequences. Therefore, the location of 
the target, ASO length and ASO chemistry play critical roles in determining the extent of 
antisense response. In vivo efficacy of an ASO is dependent upon additional factors 
including but not limited to dose, frequency, route and method of administration. The 
specific animal model and immune tolerance for the administered ASO also critically 
influence the phenotype of the ASO-treated animals.  
 
ISS-N1 as a promising therapeutic target   
 
To restore SMN2 exon 7 inclusion in SMA, it is essential that splice-switching 
ASOs target an inhibitory cis-element. It is also desirable that the inhibitory cis-element 
is located within an intronic sequence in order to avoid interfering with the translation 
and transport of mRNA. Discovery of ISS-N1 (intronic splicing silencer N1) in 2006 
provided a major breakthrough for an ASO-mediated splicing correction approach in 
SMA (31). ISS-N1 is a 15-nucleotide sequence spanning the 10th to 24th positions of 
intron 7 (Fig. 1A). ISS-N1 creates a strong negative context at the 5′ splice site (5’ ss) of 
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exon 7, and ISS-N1 deletion fully restores SMN2 exon 7 inclusion (31). Remarkably, the 
deletion of ISS-N1 confers such a stimulatory effect on SMN2 exon 7 splicing that all 
known positive cis-elements within exon 7 become dispensable. Therefore, ISS-N1 is 
described as the master checkpoint of SMN2 exon 7 splicing regulation (32). The 
therapeutic efficacy of ISS-N1 was first assessed by blocking ISS-N1 using a 20-mer 
ASO (Anti-N1) carrying phosphorothioate backbone and 2′-O-methyl modification (2′-
OMe). Even at a very low concentration (5 nM), Anti-N1 substantially elevated SMN 
levels in type I SMA patient cells (31). These unprecedented results established that 
ASO-mediated sequestration of an intronic sequence could fully correct a splicing defect 
linked to an exonic mutation.   
 
Two years after the discovery of ISS-N1, the Krainer group in collaboration with 
ISIS Pharmaceuticals conducted a systematic antisense microwalk employing ASOs 
carrying phosphorothioate backbone and 2′-O-methoxyethyl modification (MOE) 
chemistry (33). MOE chemistry, a proprietary product of ISIS Pharmaceuticals, is 
considered to confer increased nuclease resistance and decrease non-specific protein 
interactions (34). The authors concluded that the stimulatory effect of ISS-N1 targeting 
MOE ASO was higher than other MOE ASOs targeting different regions of SMN2 (33). 
They independently validated the strong inhibitory nature of ISS-N1 and generated 
interest in an ASO-mediated therapy for SMA.  
 
ISS-N1 encompasses two hnRNP A1/A2 motifs and overlaps with a unique GC-
rich motif (Fig.1A; 33,35). A cytosine residue at the 10th position (10C) of intron 7 
occupies the first position of ISS-N1. Sequestration of the first five residues of ISS-N1, 
including 10C, was necessary for the stimulatory effect of the ISS-N1-targeting ASOs 
(36). Research data supports that ISS-N1-targeting ASOs stimulate SMN2 exon 7 
inclusion by reconstructing a positive context in addition to displacing inhibitory factors 
(i.e. hnRNP A1/A2) at the 5′ ss of SMN2 exon 7 (9). The 5′ ss of exon 7 is weakened by 
the presence of a number of inhibitory cis-elements (31, 35-38). The only intronic 
positive cis-element in the vicinity of the 5′ ss of SMN2 exon 7 is the U-rich clusters 
(URCs) immediately downstream of ISS-N1 (Fig. 1A) (39). In particular, URC1 and 
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URC2 have been shown to interact with T-cell-restricted intracellular antigen 1 
(TIA1) and TIA1-related (TIAR) proteins that are splicing stimulatory factors (39). 
Recently, a point mutation within the glutamine-rich domain of TIA1 has been shown 
to affect SMN2 exon 7 splicing in the patients of Welander distal myopathy (WDM), 
an adult onset autosomal-dominant disorder characterized by distal limb 
weakness (40). These findings are significant as they reveal for the first time that 
a single point mutation within a splicing factor could have adverse effect on 
SMN2 exon 7 splicing.  
 
It has been suggested that the ASO-mediated sequestration of ISS-N1 increases 
the interaction efficiency of TIA1/TIAR and/or other members of the glutamine-rich-
RNA-binding proteins that stimulate SMN2 exon 7 inclusion by binding to U-rich 
sequences immediately downstream of ISS-N1 (39). Such interaction is necessary to 
recruit U1 snRNP at the weak 5′ ss of exon 7. Recruitment of U1 snRNP at the 5′ ss is 
the first and most critical step of spliceosomal assembly, which is a multistep dynamic 
process of intron removal (41). Recent reports suggest U1 snRNP recruitment plays a 
role in regulating isoform expression and polyadenylation (42,43). Considering intron 7 
is the last intron of SMN2, it is possible that the enhanced recruitment of U1 snRNP 
upon sequestration of ISS-N1 provides additional benefits unrelated to splicing.  
 
In vivo studies with ISS-N1 targeting ASOs  
 
The first in vivo study of an ISS-N1 targeting ASO was conducted by Williams et 
al. with a 20-mer 2′-OMe ASO (SMA AO) employing the Δ7-SMA mouse model (44). 
The median survival age of Δ7-SMA mice is ~13 days, and this model has been widely 
used for understanding the pathogenesis of SMA as well as pre-clinical testing of 
potential SMA drugs (45-49). This particular study administered ASOs on P1, 3, 5, 7, 
and 10 by bilateral intracerebroventricular (ICV) injections (1 µg per lateral ventricle), 
and tissues were harvested for analysis at P12. SMA AO increased SMN levels in brain 
and spinal cord, whereas control AO had no appreciable effect. In addition, SMA AO 
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increased body weight and improved righting reflex of the Δ7-SMA mice, whereas 
control AO provided no phenotypic benefit. Despite the limited nature of this study, the 
findings were encouraging for subsequent studies that employed different 
oligonucleotide chemistries, routes of oligonucleotide delivery and mouse models.   
 
The Krainer group at Cold Spring Harbor Laboratory in collaboration with ISIS 
Pharmaceuticals conducted a series of in vivo studies with ISS-N1 targeting MOE ASOs 
(50-52). In particular, they used an 18-mer MOE ASO (ASO-10-27) that sequesters the 
entire ISS-N1 and three residues downstream of ISS-N1 (Fig. 1B). The initial study 
employed a mild SMA model (Taiwanese SMA model; four copies of SMN2) that 
displays tail and ear necroses (53). As expected, ICV injections of ASO-10-27 in adult 
mice stimulated SMN2 exon 7 inclusion in brain and spinal cord (50), and 
immunostaining confirmed the ASO-induced upregulation of SMN in brain and spinal 
cord. Single embryonic or neonatal ICV injection of ASO-10-27 successfully rescued the 
phenotype. For instance, tail and ear necroses were either completely prevented or 
substantially delayed by treatment with ASO-10-27. Embryonic injections were more 
effective than neonatal injections. Overall, the study demonstrated the efficacy of MOE 
ASO in treating mild SMA mice when given very early. 
 
The authors also compared the MOE ASO (ASO-10-27) with the 2′-OMe ASO 
used by Williams et al. (44,50).  In contrast to the results obtained by Williams et al. in 
Δ7-SMA mice (44), ICV injection of 2′-OMe ASO in the Taiwanese SMA model did not 
stimulate SMN2 exon 7 inclusion (50). In addition, the 2′-OMe ASO, but not the MOE 
ASO, produced proinflammatory effects. The discrepancy between these two studies is 
not entirely unexpected since they used different sources of 2′-OMe oligonucleotide 
synthesis and different mouse models (Fig. 1B). A recent study that involved repeated 
long-term subcutaneous treatment of Duchenne muscular dystrophy (DMD) mice with a 
2′-OMe ASO produced tangible therapeutic benefits without any safety concerns (54). 
Therefore, it is possible that the proinflammatory effect of 2′-OMe ASO is a 
characteristic of the Taiwanese SMA model, and/or this model is more tolerant to MOE 
chemistry than to 2′-OMe chemistry. Recently, the Lorson group used a third source of 
Review Article • DOI: 10.2478/s13380-013-0109-2 • Translational Neuroscience • 4(1) • 2013 • 1-7 
 8 
oligonucleotide synthesis and independently confirmed upregulation of SMN levels in 
brain and spinal cord upon ICV administration of an ISS-N1-targeting 2′-OMe ASO in 
Δ7-SMA mice (55). 
 
The Passini group at Genzyme Corporation, in collaboration with the Krainer 
group and ISIS Pharmaceuticals, tested the efficacy of ASO-10-27 in Δ7-SMA mice 
(51). A single ICV injection of ASO-10-27 (4 µg) at P0 increased median life expectancy 
from 16 to 26 days. Treated mice had increased numbers of motor neurons within the 
spinal cord and improved motor function. Interestingly, higher and lower doses of ASO 
delivered by ICV were less effective. The authors also performed preliminary 
experiments in nonhuman primates (NHP) and demonstrated that 1) intrathecal infusion 
over a 24 hr period of a fixed dose of ASO 10-27 (3 mg) was well tolerated and could 
achieve therapeutically relevant levels of ASO 10-27 and 2) intrathecal infusion is an 
effective delivery method for global distribution of ASOs to the spinal cord of NHPs.  
The latter finding will be important for the future therapeutic development of other ASOs 
for SMA, and more broadly for other therapies that will require delivery to the spinal cord 
(51).  
 
Encouraged by the results of ICV injections of MOE ASOs in two SMA mouse 
models (50,51), the Krainer group in collaboration with ISIS Pharmaceuticals performed 
an elaborate study using the Taiwanese type I SMA mice (two copies of SMN2), a more 
severe SMA mouse model (52). This model was generated from mild Taiwanese SMA 
mice and has a median lifespan of ~10 days (56,57). The major finding of this study was 
an unexpectedly high efficacy of ASO-10-27 when delivered peripherally (52). The 
animals tolerated a very high dose of subcutaneously (SC) administered ASO-10-27. 
The best survival outcome was observed when animals received two SC 
administrations (one at P0-P1 and the other at P2-P3) each at 160 µg/g body weight 
(52). The median life expectancy of treated mice increased ~25 fold (from ~10 days to 
~273 days). Interestingly, ICV delivery was substantially less efficacious than SC 
delivery. For instance, ICV delivery of ASO-10-27 (20 µg) at P1 only increased median 
life expectancy of Taiwanese type 1 SMA mice from 10 days to 16 days (52). Although 
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somewhat controversial, these results underscore the peripheral requirement of SMN 
protein and demonstrate the long-term benefits of early ASO administration in severe 
SMA mice.  
 
In vivo studies with ISS-N1 targeting morpholinos  
 
Phosphorodiamidate morpholino oligomers (PMOs) are a class of compounds in 
which the ribose sugar moiety is replaced with a morpholino ring and the 
phosphorothioate group is replaced with an uncharged phosphorodiamidate group. 
PMOs and their derivatives have been widely used for therapeutic splicing correction in 
animal models (18,58,59). Porensky and coworkers from the Burghes laboratory 
employed Δ7-SMA mice to test the efficacy of an ISS-N1 targeting PMO (HSMN2Ex7D) 
that sequestered the entire ISS-N1 and 5 residues downstream of ISS-N1 (60; Fig. 1B). 
ICV administration of HSMN2Ex7D corrected SMN2 exon 7 splicing and increased 
levels of SMN in brain and spinal cord. A single ICV administration of 54 µg 
HSMN2Ex7D at P0 prolonged median life expectancy of Δ7-SMA mice from ~15 days to 
more than 100 days. Interestingly, peripheral delivery of HSMN2Ex7D produced no 
therapeutic benefit in Δ7-SMA mice. These results are consistent with the prevailing 
view that brain and spinal cord are the primary tissues in which high levels of SMN are 
required for an effective SMA therapy. The results also demonstrate PMO as superior to 
MOE chemistry when delivered through ICV injections.  
 
A recent study by the Muntoni group and coworkers utilizing Taiwanese type I 
SMA mice independently confirmed the high therapeutic efficacy of ISS-N1 targeting 
PMOs (61).  The authors used PMOs of three different sizes and showed 25-mer PMO 
(PMO25) that sequestered the entire ISS-N1 and 10 residues downstream of ISS-N1 
conferred better therapeutic efficacy than the 18-mer or 20-mer PMO (Fig. 1B). A single 
ICV administration of PMO25 (40 µg/g body weight) at P0 increased median life 
expectancy of Taiwanese type I SMA mice from ~10 days to more than 200 days. 
Contrary to findings in the Δ7-SMA mouse model (60), the authors found no significant 
difference in therapeutic efficacy of PMOs when delivered peripherally or ICV (61). 
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These results again underscore the difference between the Δ7-SMA and Taiwanese 
type I SMA models with regards to the efficacy of an identical ASO.  The observation 
that peripheral delivery of MOE and PMO25 has therapeutic benefit in the Taiwanese 
type I SMA model but not in the Δ7-SMA model supports that timings of BBB formation 
between these two mouse models could be distinct.  
 
 
In vivo studies with ISS-N1 targeting bifunctional ASOs  
 
Bifunctional ASOs anneal to specific RNA sequences and recruit additional 
factors through hanging tails (62). The Lorson group used bifunctional 2′-OMe ASOs to 
block ISS-N1 and recruit either Tra2-β1 or SF2/ASF in the vicinity of ISS-N1 (55). Upon 
ICV administration (6 µg/day) at P1, P3 and P5, these ASOs increased weight and 
gross motor functions of Δ7-SMA mice. Treatment also increased the median life 
expectancy of Δ7-SMA mice from ~16 days to 18-20 days. The efficacy of the ASO 
carrying a Tra2-β1 motif was higher than the ASO carrying a SF2/ASF motif; however, 
the therapeutic benefit of these bifunctional ASOs was substantially lower than ISS-N1-
targeting MOEs and PMOs (52,60,61).  
 
The low efficacy of ISS-N1 targeting bifunctional ASOs could result from a limited 
ability of Tra2-β1 and/or SF2/ASF to activate the 5′ ss of SMN2 exon 7.  Since these 
bifunctional ASOs are larger, they may fold into secondary and/or higher order 
structures that could sequester critical residues responsible for annealing and/or protein 
recruitment. In addition, large oligonucleotides are notorious for non-specific trapping of 
protein factors. Some of these problems could be overcome through trial and error by 
testing different tailed sequences in the context of different chemistries. However, since 
a bifunctional ASO is designed to trap an arbitrary chosen splicing factor, there is a risk 
of unwanted secondary effect on splicing of other genes. 
 
Other ASO-based approaches  
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Several other ASO-based studies independent of ISS-N1 have been used for 
splice correction in SMA. A bifunctional ASO targeting element 1 located within intron 6 
exhibited efficacy in SMA mice (63,64). Other bifunctional ASOs that anneal to SMN2 
exon 7 and recruit splicing factors either at the 3′ or 5′ ss of exon 7 have shown 
encouraging results in vitro, ex vivo and in SMA mice (65-68). Blocking the 3′ ss of exon 
8 by an ASO embedded in U7 snRNAs was shown to prevent exon 7 skipping and 
increase SMN levels in SMA patient-derived cells (69). These results underscore that 
the transcripts retaining SMN2 intron 7 are capable of being polyadenylated, exported 
out of the nucleus, and translated in the cytoplasm. Recently, an 8-mer ASO (3UP8) 
that sequesters a GC-rich sequence within intron 7 was shown to have a strong 
stimulatory effect on SMN2 exon 7 inclusion in SMA patient fibroblast cell lines (35,70). 
In addition to being cost effective, small ASOs offer the advantage of being less tolerant 
towards non-canonical and mismatch base pairing, a major cause for the nonspecific 
effect associated with large ASOs. Consistently, 3UP8 showed zero tolerance for a 
single mismatch base pair mutation at the target site (35). However, it remains to be 
seen whether the expected benefit of a small ASO is realized in a mouse model of 
SMA.  
 
Conclusions and future directions 
 
SMA is a rare disease in which a correctable copy of the gene (SMN2) is 
universally present in all SMA patients. In addition, SMA is unique in that all patients 
have the opportunity for an ASO-based therapy to increase SMN levels by correcting 
the pre-mRNA splicing of one exon.   In the absence of structure-specific targets, an 
ASO-based approach remains the best option for gene-specific splicing correction. In 
general, the success of an ASO-based approach for splicing correction depends on the 
potency of the target.  Characterizing an efficient intronic target for inducing exon 
inclusion remains a challenging endeavor.  
 
The discovery of ISS-N1 provided a major breakthrough as it demonstrated for 
the first time that a large intronic motif could serve as a master regulator of SMN2 exon 
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7 splicing. The finding that an ASO-mediated sequestration of ISS-N1 fully restores 
SMN2 exon 7 inclusion led to several in vivo studies in mouse models of SMA. 
Consistently, ISS-N1 stands as the most scrutinized antisense target for the potential 
treatment of a genetic disease. The last few years have witnessed remarkable progress 
towards the development of ISS-N1-based therapy. For instance, ISIS Pharmaceuticals 
successfully concluded a phase 1 clinical trial of ISIS-SMNRx, an ISS-N1 targeting ASO 
with MOE chemistry. This is the first clinical trial for an ASO-mediated restoration of 
exon inclusion in a human disease. Consistent with the results in NHP (51), intrathecal 
infusion of ISIS-SMNRx was well tolerated in SMA patients during phase 1 clinical trial. If 
successful, this would be the first mechanism-based therapy for SMA.  
 
The great promise of an ASO based therapy is derived from the limitless number 
of compounds that could be tested against the same target. Two recent pre-clinical 
studies conducted independently support ISS-N1 targeting PMOs as an entirely 
different class of very effectives ASOs (60,61). When delivered peripherally, ISS-N1 
targeting PMOs appear to offer an advantage of being active at a substantially lower 
dose than a MOE ASO (52,61). In a recent Duchenne muscular dystrophy clinical trial, 
PMO backbone was well tolerated when delivered systemically (71). However, it 
remains to be seen whether intrathecal administration of PMOs are tolerated in NHPs. It 
will be also tempting to determine if systemic delivery of PMOs is a viable alternative in 
SMA. Although in preliminary stages, bifunctional and small ASOs hold potential to offer 
additional antisense compounds. With the ongoing progress in clinical trials and 
advancement in oligonucleotide chemistry and delivery schemes, it is only a matter of 
time until an array of effective ASO-based drugs becomes available for the treatment of 
SMA, a devastating disease of children and infants.  The lessons learned from ASO-
based therapy development in SMA will be extremely informative for other diseases that 
could utilize similar approaches.   
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Figure Legend: 
 
Figure 1. ASO-mediated splicing correction in SMA. (A) Diagrammatic representation of 
splicing cis elements. Splicing cis-elements are indicated by boxes. Numbering starts 
from the first position of SMN2 intron 7. Cis-elements shown here are described in detail 
in a recent review by Singh and Singh (9). ISS-N1 is negative cis-element that has 
emerged as the leading therapeutic target for an ASO-mediated splicing correction in 
SMA (31-33, 50-52, 55,60,61). Binding sites of inhibitory factor hnRNP A1 (33) and 
stimulatory factors TIA1 and TIAR (39) have been indicated. GC-rich sequence 
constitutes the target for splicing correction by the shortest ASO (35). A cytosine residue 
at the 10th intronic position (10C) associates with a long-distance interaction (LDI) with 
the downstream intronic sequences (36). Sequestration of ISS-N1 or GC-rich sequence 
appears to abrogate the inhibitory LDI associated with 10C. (B) Diagrammatic 
representation of annealing positions of ISS-N1 targeting ASOs. All ISS-N1 targeting 
ASOs sequestered the first residue of ISS-N1. Reference numbers of studies using 
different ASOs targeting ISS-N1 are shown. Abbreviations: ISS-N1, Intronic splicing 
silencer N1; LDI, long-distance interaction; URC, U-rich cluster; ASO, antisense 
oligonucleotide; 2′-OMe, an ASO with phosphorothioate backbone and 2′-O-methyl 
modification; MOE, an ASO with phosphorothioate backbone and 2′-O-methoxyethyl 
modification; Δ7-SMA, severe SMA model (45); NHP, non-human primate; Mild-TW, mild 
Taiwanese model of SMA (53); Severe-TW, severe Taiwanese model of SMA (56,57).  
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